Targeting protein acetylation for improving cancer therapy

Indian Journal of Medical Research

Volumn 128, Issue 1, 2008, Pages 13-21

  Dwarakanath, B S ^a   Verma, Amit ^a   Bhatt, A N ^a   Parmar, V S ^a   Raj, H G ^b  

^a UNIVERSITY OF DELHI   (India)

^b UNIVERSITY OF DELHI   (India)

Author keywords

Calreticulin; Histone acetyl transferases; Histone deacetylase inhibitors; Histone deacetylases; Polyphenolic acetates

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 7 ACETOXY 4 METHYLCOUMARIN; 7,8 DIACETOXY 4 METHYLCOUMARIN; AG 957; ALPHA TUBULIN; ANTINEOPLASTIC AGENT; ARYLBUTYRIC ACID DERIVATIVE; BUTYRIC ACID; CAMPTOTHECIN; CISPLATIN; DNA; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; MYC PROTEIN; QUERCETIN; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR GATA 1; TRASTUZUMAB; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; WORTMANNIN;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE REGULATION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXICITY; DEACETYLATION; DNA REPAIR; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SENSITIVITY; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION; GLIOMA; HEMATOLOGIC MALIGNANCY; HUMAN; NONHUMAN; PROTEIN DNA BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; SOLID TUMOR;

ACETYLATION; ANTINEOPLASTIC AGENTS; HISTONES; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 55849096208     PISSN: 09715916     EISSN: 09715916     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
2. Milin RA, Alex S, Jurgen V, William DF. Rational development of histone deacetylase inhibitors as anticancer agents. Mol Pharmacol 2005; 68: 917-32.
3. Hake SB, Xiao A, Allis CD. Linking the epigenetic language of covalent histone modifications to cancer. Br J Cancer 2004; 90: 761-9.
4. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4: 988-93.
5. Waterborg JH. Dynamics of histone acetylation in vivo. A function for acetylation turnover? Biochem Cell Biol 2002; 80: 363-78.
6. Sakaguchi K, Herrera JE, Soutos, Mirkit, Bustin M, Vassilev A, et al. DNA damage activates p53 through a phosphorylationacetylation cascade. Genes Dev 1998; 12: 2831-41.
7. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann NY Acad Sci 2003; 983: 84-100.
8. Peip, El-Deiery WS. p53 and radiation responses. Oncogene 2003; 22: 5774-83.
9. Karin, M. How NF-kappa B is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 1999; 18: 6867-74.
10. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
11. Hu Y, Qiao L, Wang S, Rong SB, Meuillet EJ, Berggren M, Gallegos A. 3-(Hydroymethyl)-bearing phophatidylinositol ether lipid analogues and carbonate surrogates block PI3-K, Akt, and cancer cell growth. J Med Chem 2000; 43: 3045-51.
12. Yang, X, Phillips DL, Ferguson AT, Nelson WG, Herman JG, Davidson NE. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyl transferase asl and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells. Cancer Res 2001; 61: 7025-9.
13. Perez-Lamigueiro MA, Alvarez-Gonzalez R. Polynucleosomal synthesis of poly (ADP-ribose) causes chromatin unfolding as determined by micrococcal nuclease digestion. Ann NY Acad Sci 2004; 1030: 593-8.
14. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90: 595-606.
15. Chen LF, Mu Y, Greene WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J 2002; 21: 6539-48.
16. Gronroos E, Hellman U, Heldin CH, Ericsson J. Control of Smad7 stability by competition between acetylation and ubiqutination. Mol Cell 2002; 10: 483-93.
17. Seigneurin-Burnj D, Verdel A, Curtet S, Lemercier C, Garin J, Rousseaux S, et al. Identification of components of the murine histone deacetylase 6 complex: link between acetylation and ubiquitination signaling pathways. Mol Cell Biol 2001; 21: 8035-44.
18. Caron C, Boyault C, Khochbin S. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability Bioessays 2005; 27: 408-15.
19. Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene 2007; 26: 5310-18.
20. Cohen T, Yao TP. AcK-knowledge reversible acetylation. Sci STKE (Signal transduction knowledge environment) 2004; pe 42: 1-30
21. Yang XJ, Gre'goire S. Metabolism, cytoskeleton and cellular signalling in the grip of protein Nepsilon- and O-acetylation. EMBO Rep 2007; 8: 556-62.
22. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, et al. DNA damage activates p53 through a phosphorylationacetylation cascade. Genes Dev 1998; 12: 2831-41.
23. Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J 2000; 19: 1176-9.
24. Takemura R, Okabe S, Umeyama T, Kanai Y, Cowan NJ, Hirokawa N. Increased microtubule stability and alpha tubulin acetylation in cells transfected with microtubule-associated proteins MAP1B, MAP2 or tau. J Cell Sci 1992; 103: 953-64.
25. Martinez-Balbás MA, Bauer UM., Nielsen SJ, Brehm A, Kouzarides T. Regulation of E2F-activity by acetylation. EMBO J 2000; 19: 662-71.
26. Chen LF, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-êappaB action regulated by reversible acetylation. Science 2001; 293: 1653-7.
27. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, et al. MDM2-HDAC1 - mediated deacetylation of p53 is required for its degradation. EMBO J 2002; 21: 6236-45.
28. Simonsson M, Heldinch, Ericsson J, Gronroos E. The balance between acetylation and deacetylation controls Smad7 stability. J Biol Chem 2005; 280: 21797-803.
29. Grant PA. A tale of histone modifications. Genome Biol 2001; 2: REVIEWS. 0003.1-0003.6.
30. Kuo MH, Brownell JE, Sobel RE, Ranalli TA, Cook RG, Edmondson DG, et al. Transcription-linked acetylation by GCN5p of histones H3 and H4 at specific lysines. Nature 1996; 383: 269-72.
31. Moralis V, Helene Richard-Foyn. Role of histone N-terminal tails and their acetylation in nucleosome dynamics. Mol Cell Biol 2000; 20: 7230-37.
32. He S, Bauman D, Davis JS, Loyola A, Nishioka K, Grolund JL, et al. Facile synthesis of site-specifically acetylated and methylated histone proteins: reagents for evaluation of the histone code hypothesis. Proc Nat Acad Sci USA 2003; 100: 12033-8.
33. Kadosh D, Struhl K. Repression by Ume6 involves recruitment of a complex containing Sin3 corepressor and Rpd3 histone deacetylase to target promoters. Cell 1997; 89: 365-71.
34. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998; 20: 615-626.
35. Lim JH, West KL, Rubinstein Y, Bergel M, Postnikov YV, Bustin M. Chromosomal protein HMGN1 enhances the acetylation of lysine 14 in histone H3. EMBO J 2005; 24: 3038-48.
36. Sterner DE, Berger SL. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 2000; 64: 435-59.
37. Ruijter De MJ, Annmieke, Gennip Van H Albert, Caron N Huib, Kemp S, Kuilenburg van PB Andre. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J 2003; 370: 737-49.
38. Roth SY, Allis CD. Histone acetylation and chromatin assembly: a single escort, multiple dances? Cell 1996; 87: 5-8.
39. Candau R, Zhou JX, Allis CD, Berger SL. Histone acetyltransferase activity and interaction with ADA2 are critical for GCN5 function in vivo. EMBO J 1997; 16: 555-65.
40. Kuo MH, Brownell JE, Sobel RE, Ranalli TA, Cook RG, Edmondson DG, et al. Transcription-linked acetylvation by GCN5P of histones H3 and H4 at specific lysines. Nature 1996; 383: 269-72.
41. Borrow J, Stanton VP Jr, Andresen JM, Becher R, Behm FG, Chaganti RS, et al. The translocation t (8; 16) (p11; p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996; 14: 33-41.
42. Yang XJ, Ogryzko VV, Nishikawa J, Howard BH, Nakatani Y. A p300/ CBP-associated factor that competes with the adenoviral. Oncoprotein E1A. Nature 1996; 382: 319-24.
43. Chakravarti D, Ogryzko V, Kao HY, Nash A, Chen H, Nakatani Y, et al. A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell 1999; 96: 393-403.
44. Hamamori Y, Sartorelli V, Ogryzko V, Puri PL, Wu HY, Wang JY, et al. Regulation of histone acetyltransferases p300 and PCAF by the DHLH protein twist and adenoviral oncoprotein E1A. Cell 1999; 96: 405-13.
45. Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene 2007; 26: 5420-32.
46. Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000; 184: 1-16.
47. Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci 2001; 58: 728-36.
48. Munster PN, Troso Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoyanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res 2001; 61: 8492-7.
49. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002; 21: 6236-45.
50. Yan L, Yang X, Davidson NE. Role of DNA methylation and histone acetylation in steroid receptor expression in breast cancer. J Mammary Gland Biol Neoplasia 2001; 6: 183-92.
51. Kouraklis G, Misiakos EP, Theocharis S. Histone deacetylase inhibitors as a potential therapeutic agent for human cancer treatment. Targ Oncol 2006; 1: 34-41
52. Pandolfi PP. Histone deacetylases and transcriptional therapy with their inhibitors. Cancer Chemother Pharmacol 2001; 48 (Suppl 1): S17-9.
53. Gallinari P, Di Marco S, Jones P, Pallaoro M, Steinkuhler C. HDACs, histone deacetylation and gene transcription:from molecular biology to cancer therapeutics. Cell Res 2007; 17: 195-211.
54. Yoshida M, Furumai R, Nishiyama M, Komatsu Y, Nishino N, Horinouchi S Histone deacetylase as a new target for cancer chemotherapy. Cancer Chemother Pharmacol 2001; 48 (Suppl1): S20-6.
55. Herold C, Ganslmayer M, Ocker M, Hermann M, Geerts A, Hahn EG, et al. The histone deacetylase inhibitor trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol 2002; 36: 233-40.
56. Hoshikawa Y, Kwon HJ, Yoshida M, Horinouchi S, Beppu T. Trichostatin A induces morphological changes and gelsolin expression by inhibiting histone deacetylase in human carcinoma cell lines. Exp Cell Res 1994; 214: 189-97.
57. Strait KA, Dabbas B, Hammond EH, Warnick CT, Iistrup SJ, Ford CD. Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther 2002; 1: 1181-90.
58. Marks PA. The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Cell Cycle 2004; 3: 534-5.
59. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 1998; 95: 3003-7.
60. Richon VM, Zhou X, Rifkind RA, Marks PA. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers. Blood Cells Mol Dis 2001; 27: 260-4.
61. Huang L, Pardee AB. Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med 2000; 6: 849-66.
62. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, et al. Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid(SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 1999; 18: 7016-25.
63. Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind AR, et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 2001; 61: 3591-4.
64. Richon VM, Webb Y, Merger R, Sheppard T, Jursic B, Ngo L, et al. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. Proc Natl Acad Sci U S A 1996; 93: 5705-8.
65. Nackerdien Z, Michie J, Bohm L. Chromatin decondensed by acetylation shows an elevated radiation response. Radiat Res 1989; 117: 234-44.
66. Kim J H, Jin H S, Eui K C, Hong-G W, Jae S K, Han K, et al. Trichostatin A, a histone deacetylase inhibitor, potentiated cytotoxic effect of ionizing radiation in human head and neck cancer cell lines. J Korean Soc Ther Radiol Oncol 2004; 22: 138-44.
67. Kim MS, Blake M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Res 2003; 63: 7291-300.
68. Huang Y, Waxman S. Enhanced growth inhibition and differentiation of fluorodeoxyuridine-treated human colon carcinoma cells by phenylbutyrate. Clin Cancer Res 1998; 4: 2503-9.
69. Huang Y, Horvath CM, Waxman S. Regrowth of 5-fluorouracil-treated human colon cancer cells is prevented by the combination of interferon gamma, indomethacin and phenylbutyrate. Cancer Res 2000; 60: 3200-6.
70. Fuino L, Bali P, Wittmann S, Donapaty S, Guo F, Yamaguchi H, et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine and epothilone B. Mol Cancer Ther 2003; 2: 971-84.
71. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nat NewBiol 1971; 231: 232-5.
72. Raj HG, Kohli E, Goswami R, Goel S, Rastogi RC, Jain SC, et al. Mechanism of biochemical action of substituted Benzopyran-2-ones, part 8: Acetoxycoumarin: protein transacetylase-specificity for aromatic nuclear acetoxy groups in proximity to the oxygen heteroatom. Bioorg Med Chem 2001; 9: 1085-9.
73. Seema, Kumari R, Gupta G, Saluja D, Kumar A, Goel S, et al. Characterization of protein transacetylase from human placenta as a signaling molecule calreticulin using polyphenolic peracetates as the acetyl group donors. Cell Biochem Biophysics 2007; 47: 53-64.
74. Kohli E, Gaspari M, Raj HG, Parmar VS, Vender Greef J, Gupta G, et al. Establishment of the enzymatic protein acetylation independent of acetyl CoA: recombinant glutathione S- transferase 3-3 is acetylated by a novel membrane-bound transacetylase using 7, 8-diacetoxy-4-methyl coumarin as the acetyl donor.FEBS Lett 2002; 530: 139-42.
75. Kohli E, Gaspari M, Raj HG, Parmar VS, Sharma SK, Vander Greef J, et al. Acetoxy drug: protein transacetylase of buffalo liver-characterization and mass spectrometry of the acetylated protein product. Biochim Biophys Acta 2004; 1698: 55-66.
76. Khurana P, Kumari R, Vohra P, Kumar Ajit, Seema, Gupta Garima. Acetoxy drug: protein transacetylase catalyzed activation of human platelet nitric oxide synthase by polyphenolic peracetates. Bioorg Med Chem 2006; 14: 575-83.
77. Hodawadekar SC, Marmorstein R. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene 2007; 26: 5528-40.
78. 1-induced micronuclei and apoptosis in lung and bone marrow cells. Mutat Res 2001; 494: 31-40.
79. Herbert V. Prooxidant effects of antioxidant vitamins. introduction. J Nutr. 1996; 126 (4 Suppl): 1197S-200S.
80. Koshy L, Dwarakanath BS, Raj HG, Chandra R, Mathew Lazar T. Suicidal oxidative stress induced by certain antioxidants. Indian J Exp Biol 2003; 41: 1273-8.